Market overview
The global proton therapy market is worth USD 1.4 bn in 2026 and is forecast to reach USD 2.9 bn by 2036, growing at a 8.0% CAGR. United States is the largest country market and Multi-room is the largest by system type segment.
| Scope | Proton therapy systems for cancer radiotherapy: accelerators, gantries and treatment rooms, with installation, upgrades and service contracts. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 1.2 bn |
| Value 2026 | USD 1.4 bn |
| Value 2036 | USD 2.9 bn |
| CAGR 2026-2036 | 8.0% |
| Volume 2026 | 53.2 treatment rooms |
| Volume 2036 | 99.0 treatment rooms |
| Average price 2026 | USD 25,370,000 per treatment room |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Proton Therapy market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 1.4 bn |
| 2027 | USD 1.5 bn |
| 2028 | USD 1.6 bn |
| 2029 | USD 1.7 bn |
| 2030 | USD 1.8 bn |
| 2031 | USD 2.0 bn |
| 2032 | USD 2.1 bn |
| 2033 | USD 2.3 bn |
| 2034 | USD 2.5 bn |
| 2035 | USD 2.7 bn |
| 2036 | USD 2.9 bn |
Proton Therapy market segmentation
By system type
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Multi-room | 50.0% | 37.4% | USD 675 mn | 4.9% |
| Single-room compact | 38.0% | 43.1% | USD 513 mn | 9.4% |
| Ultra-compact and upright-positioning | 12.0% | 19.5% | USD 162 mn | 13.4% |
By accelerator
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Cyclotron | 70.0% | 65.5% | USD 945 mn | 7.3% |
| Synchrocyclotron | 18.0% | 24.3% | USD 243 mn | 11.3% |
| Synchrotron | 12.0% | 10.2% | USD 162 mn | 6.3% |
By end user
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Hospitals | 55.0% | 55.3% | USD 742 mn | 8.1% |
| Cancer centres | 30.0% | 31.6% | USD 405 mn | 8.6% |
| Research institutes | 15.0% | 13.1% | USD 202 mn | 6.6% |
By treatment site
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Prostate | 36.0% | 34.0% | USD 486 mn | 7.4% |
| Head and neck | 20.0% | 20.0% | USD 270 mn | 8.0% |
| Brain and spine | 12.0% | 12.0% | USD 162 mn | 8.0% |
| Breast | 12.0% | 14.0% | USD 162 mn | 9.7% |
| Lung and other | 20.0% | 20.0% | USD 270 mn | 8.0% |
By delivery
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Pencil beam scanning | 62.0% | 70.0% | USD 837 mn | 9.3% |
| Passive scattering | 28.0% | 16.0% | USD 378 mn | 2.1% |
| Hybrid and FLASH-ready | 10.0% | 14.0% | USD 135 mn | 11.7% |
Top 25 countries for proton therapy by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 80.5% of 2026 revenue and the 25 countries below together hold 94.2%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 405 mn | 30.0% | USD 813 mn | 7.2% |
| 2 | Japan | USD 189 mn | 14.0% | USD 344 mn | 6.2% |
| 3 | China | USD 135 mn | 10.0% | USD 391 mn | 11.2% |
| 4 | Germany | USD 94 mn | 7.0% | USD 181 mn | 6.7% |
| 5 | France | USD 54 mn | 4.0% | USD 108 mn | 7.2% |
| 6 | United Kingdom | USD 54 mn | 4.0% | USD 108 mn | 7.2% |
| 7 | Netherlands | USD 40 mn | 3.0% | USD 82 mn | 7.3% |
| 8 | Italy | USD 40 mn | 3.0% | USD 82 mn | 7.3% |
| 9 | South Korea | USD 40 mn | 3.0% | USD 99 mn | 9.4% |
| 10 | India | USD 34 mn | 2.5% | USD 128 mn | 14.3% |
| 11 | Switzerland | USD 33 mn | 2.4% | USD 71 mn | 8.0% |
| 12 | Canada | USD 26 mn | 1.9% | USD 54 mn | 7.7% |
| 13 | Australia | USD 19 mn | 1.4% | USD 40 mn | 7.6% |
| 14 | Spain | USD 15 mn | 1.1% | USD 32 mn | 7.6% |
| 15 | Belgium | USD 13 mn | 1.0% | USD 27 mn | 7.7% |
| 16 | Sweden | USD 11 mn | 0.8% | USD 24 mn | 7.6% |
| 17 | Taiwan | USD 10 mn | 0.8% | USD 21 mn | 7.6% |
| 18 | Saudi Arabia | USD 9.2 mn | 0.7% | USD 27 mn | 11.4% |
| 19 | Austria | USD 8.4 mn | 0.6% | USD 17 mn | 7.7% |
| 20 | Poland | USD 7.7 mn | 0.6% | USD 23 mn | 11.4% |
| 21 | Czech Republic | USD 7.2 mn | 0.5% | USD 15 mn | 7.6% |
| 22 | Denmark | USD 6.8 mn | 0.5% | USD 14 mn | 7.6% |
| 23 | Israel | USD 6.3 mn | 0.5% | USD 19 mn | 11.4% |
| 24 | Thailand | USD 5.9 mn | 0.4% | USD 18 mn | 11.6% |
| 25 | Egypt | USD 5.7 mn | 0.4% | USD 17 mn | 11.5% |
| Rest of world | USD 79 mn | 5.8% | USD 163 mn | 7.5% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- IBA
- Varian
- Hitachi
- Sumitomo Heavy Industries
Group 2: Regional and specialist players
- Mevion Medical Systems
- Mitsubishi Electric
- Toshiba Energy Systems
- Optivus Proton Therapy
- Shanghai APACTRON Particle Equipment
Group 3: Emerging and niche players
- ProTom International
- CAS Ion Medical and Technology
- P-Cure
- Advanced Oncotherapy
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the proton therapy market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 8.0% is calculated from the resulting values.
The market is divided by system type, by accelerator, by end user, by treatment site, by delivery. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the proton therapy market?
The global proton therapy market is estimated at USD 1.2 bn in 2025 and USD 1.4 bn in 2026.
How fast will the proton therapy market grow?
It is forecast to reach USD 2.9 bn by 2036, a compound annual growth rate of 8.0% from 2026, an increase of USD 1.6 bn.
Which country is the largest market for proton therapy?
United States is the largest market by revenue at USD 405 mn in 2026, 30.0% of the global total. The three largest countries together hold 54.0%.
Which country is growing fastest?
Among the ten largest markets, India is growing fastest at 14.3% a year from 2026 to 2036.
Which proton therapy segment is largest?
In the by system type split, Multi-room is the largest segment with 50.0% of 2026 revenue.
Who are the leading proton therapy companies?
Global leaders include IBA, Varian, Hitachi, Sumitomo Heavy Industries.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- AI-Driven Cardiac DiagnosticsUSD 1.3 bn · 16.0% CAGR
- Urethral Balloon CathetersUSD 1.4 bn · 4.3% CAGR
- Eosinophilic EsophagitisUSD 1.4 bn · 12.0% CAGR
- Frozen Clinical MealUSD 1.3 bn · 3.8% CAGR
- Blister MachineUSD 1.4 bn · 5.5% CAGR
- Organ Preservation & Perfusion ProductsUSD 1.4 bn · 11.0% CAGR
- Muscle Stimulation DevicesUSD 1.4 bn · 5.8% CAGR
- Medical PendantUSD 1.3 bn · 6.0% CAGR